Skip to main content

Advertisement

SpringerLink
Log in

MicroRNA as potential biomarkers in Glioblastoma

  • Topic Review
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Glioblastoma is the most aggressive and lethal tumour of the central nervous system and as such the identification of reliable prognostic and predictive biomarkers for patient survival and tumour recurrence is paramount. MicroRNA detection has rapidly emerged as potential biomarkers, in patients with glioblastoma. Over the last decade, analysis of miRNA in laboratory based studies have yielded several candidates as potential biomarkers however, the accepted use of these candidates in the clinic is yet to be validated. Here we will examine the use of miRNA signatures to improve glioblastoma stratification into subgroups and summarise recent advances made in miRNA examination as potential biomarkers for glioblastoma progression and recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Goodenberger ML, Jenkins RB (2012) Genetics of adult glioma. Cancer Genet. 205(12):613–621

    Article  CAS  PubMed  Google Scholar 

  2. Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY (2012) Primary brain tumours in adults. Lancet 379(9830):1984–1996

    Article  PubMed  Google Scholar 

  3. Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF et al (2012) Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 26(8):756–784

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807–1812

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol. 14(Suppl 5):v1–v49

    Article  PubMed Central  PubMed  Google Scholar 

  6. Abrams DA, Hanson JA, Brown JM, Hsu FP, Delashaw JB Jr, Bota DA (2015) Timing of surgery and bevacizumab therapy in neurosurgical patients with recurrent high grade glioma. J Clin Neurosci. 22(1):35–39

    Article  CAS  PubMed  Google Scholar 

  7. Jones TS, Holland EC (2012) Standard of care therapy for malignant glioma and its effect on tumor and stromal cells. Oncogene 31(16):1995–2006

    Article  CAS  PubMed  Google Scholar 

  8. Drappatz J, Norden AD, Wen PY (2009) Therapeutic strategies for inhibiting invasion in glioblastoma. Expert Rev Neurother 9(4):519–534

    Article  PubMed  Google Scholar 

  9. Cher L, Rosenthal MA, Drummond KJ, Dally M, Murphy M, Ashley D et al (2008) The use of chemotherapy in patients with gliomas: patterns of care in Victoria from 1998–2000. J Clin Neurosci. 15(4):398–401

    Article  CAS  PubMed  Google Scholar 

  10. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996

    Article  CAS  PubMed  Google Scholar 

  11. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD et al (2000) A phase II study of temozolomide versus procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83(5):588–593

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Milano MT, Okunieff P, Donatello RS, Mohile NA, Sul J, Walter KA et al (2010) Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma. Int J Radiat Oncol Biol Phys 78(4):1147–1155

    Article  CAS  PubMed  Google Scholar 

  13. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5 year analysis of the EORTC-NCIC trial. Lancet Oncol. 10(5):459–466

    Article  CAS  PubMed  Google Scholar 

  14. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15(19):6002–6007

    Article  CAS  PubMed  Google Scholar 

  15. Scherer HJ (1940) A critical review: the pathology of cerebral gliomas. J Neurol Psychiatry. 3(2):147–177

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. McDonald KL, Aw G, Kleihues P (2012) Role of biomarkers in the clinical management of glioblastomas: what are the barriers and how can we overcome them? Front Neurol. 3:188

    PubMed Central  PubMed  Google Scholar 

  17. Ohgaki H, Kleihues P (2013) The definition of primary and secondary glioblastoma. Clin Cancer Res 19(4):764–772

    Article  CAS  PubMed  Google Scholar 

  18. van den Bent MJ (2010) Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective. Acta Neuropathol 120(3):297–304

    Article  PubMed Central  PubMed  Google Scholar 

  19. Thuy MN, Kam JK, Lee GC, Tao PL, Ling DQ, Cheng M et al (2015) A novel literature-based approach to identify genetic and molecular predictors of survival in glioblastoma multiforme: analysis of 14,678 patients using systematic review and meta-analytical tools. J Clin Neurosci 22(5):785–799

    Article  CAS  PubMed  Google Scholar 

  20. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A et al (2010) A multigene predictor of outcome in glioblastoma. Neuro Oncol. 12(1):49–57

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogianakis GM et al (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 455(7216):1061–1068

    Article  CAS  Google Scholar 

  22. Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, Malmer B et al (2009) Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 41(8):899–904

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Gan HK, Kaye AH, Luwor RB (2009) The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci. 16(6):748–754

    Article  CAS  PubMed  Google Scholar 

  24. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9(3):157–173

    Article  CAS  PubMed  Google Scholar 

  25. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1):98–110

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR et al (2013) The somatic genomic landscape of glioblastoma. Cell 155(2):462–477

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP et al (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17(5):510–522

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Henriksen M, Johnsen KB, Olesen P, Pilgaard L, Duroux M (2014) MicroRNA expression signatures and their correlation with clinicopathological features in glioblastoma multiforme. Neuromol Med. 16(3):565–577

    Article  CAS  Google Scholar 

  29. Malzkorn B, Wolter M, Liesenberg F, Grzendowski M, Stuhler K, Meyer HE et al (2010) Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol 20(3):539–550

    Article  CAS  PubMed  Google Scholar 

  30. Parker NR, Correia N, Crossley B, Buckland ME, Howell VM, Wheeler HR (2013) Correlation of MicroRNA 132 up-regulation with an unfavorable clinical outcome in patients with primary glioblastoma multiforme treated with radiotherapy plus concomitant and adjuvant temozolomide chemotherapy. Transl Oncol. 6(6):742–748

    Article  PubMed Central  PubMed  Google Scholar 

  31. Brower JV, Clark PA, Lyon W, Kuo JS (2014) MicroRNAs in cancer: glioblastoma and glioblastoma cancer stem cells. Neurochem Int 77:68–77

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Low SY, Ho YK, Too HP, Yap CT, Ng WH (2014) MicroRNA as potential modulators in chemoresistant high-grade gliomas. J Clin Neurosci. 21(3):395–400

    Article  CAS  PubMed  Google Scholar 

  33. Mizoguchi M, Guan Y, Yoshimoto K, Hata N, Amano T, Nakamizo A et al (2013) Clinical implications of microRNAs in human glioblastoma. Front Oncol. 3:19

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Hermansen SK, Kristensen BW (2013) MicroRNA biomarkers in glioblastoma. J Neurooncol 114(1):13–23

    Article  CAS  PubMed  Google Scholar 

  35. Moller HG, Rasmussen AP, Andersen HH, Johnsen KB, Henriksen M, Duroux M (2013) A systematic review of microRNA in glioblastoma multiforme: micro-modulators in the mesenchymal mode of migration and invasion. Mol Neurobiol 47(1):131–144

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Piwecka M, Rolle K, Belter A, Barciszewska AM, Zywicki M, Michalak M et al (2015) Comprehensive analysis of microRNA expression profile in malignant glioma tissues. Mol Oncol 9(7):1324–1340

    Article  CAS  PubMed  Google Scholar 

  37. Qu S, Guan J, Liu Y (2015) Identification of microRNAs as novel biomarkers for glioma detection: a meta-analysis based on 11 articles. J Neurol Sci 348(1–2):181–187

    Article  CAS  PubMed  Google Scholar 

  38. Wang Y, Gao X, Wei F, Zhang X, Yu J, Zhao H et al (2014) Diagnostic and prognostic value of circulating miR-21 for cancer: a systematic review and meta-analysis. Gene 533(1):389–397

    Article  CAS  PubMed  Google Scholar 

  39. Guessous F, Alvarado-Velez M, Marcinkiewicz L, Zhang Y, Kim J, Heister S et al (2013) Oncogenic effects of miR-10b in glioblastoma stem cells. J Neurooncol 112(2):153–163

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, Hawkinson M et al (2008) microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 68(10):3566–3572

    Article  CAS  PubMed  Google Scholar 

  41. Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E et al (2009) MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res 69(19):7569–7576

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  42. Godlewski J, Nowicki MO, Bronisz A, Williams S, Otsuki A, Nuovo G et al (2008) Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res 68(22):9125–9130

    Article  CAS  PubMed  Google Scholar 

  43. Gu JJ, Gao GZ, Zhang SM (2015) miR-218 inhibits the migration and invasion of glioma U87 cells through the Slit2-Robo1 pathway. Oncol Lett. 9(4):1561–1566

    PubMed Central  PubMed  Google Scholar 

  44. Wang RJ, Li JW, Bao BH, Wu HC, Du ZH, Su JL et al (2015) MicroRNA-873 (miRNA-873) inhibits glioblastoma tumorigenesis and metastasis by suppressing the expression of IGF2BP1. J Biol Chem 290(14):8938–8948

    Article  CAS  PubMed  Google Scholar 

  45. Rao SA, Santosh V, Somasundaram K (2010) Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma. Mod Pathol 23(10):1404–1417

    Article  CAS  PubMed  Google Scholar 

  46. Guan Y, Mizoguchi M, Yoshimoto K, Hata N, Shono T, Suzuki SO et al (2010) MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. Clin Cancer Res 16(16):4289–4297

    Article  CAS  PubMed  Google Scholar 

  47. Visani M, de Biase D, Marucci G, Cerasoli S, Nigrisoli E, Bacchi Reggiani ML et al (2014) Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I-III. Mol Oncol. 8(2):417–430

    Article  CAS  PubMed  Google Scholar 

  48. Zhi F, Chen X, Wang S, Xia X, Shi Y, Guan W et al (2010) The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma. Eur J Cancer 46(9):1640–1649

    Article  CAS  PubMed  Google Scholar 

  49. Rivera-Diaz M, Miranda-Roman MA, Soto D, Quintero-Aguilo M, Ortiz-Zuazaga H, Marcos-Martinez MJ et al (2015) MicroRNA-27a distinguishes glioblastoma multiforme from diffuse and anaplastic astrocytomas and has prognostic value. Am J Cancer Res. 5(1):201–218

    PubMed Central  PubMed  Google Scholar 

  50. Berthois Y, Delfino C, Metellus P, Fina F, Nanni-Metellus I, Al Aswy H et al (2014) Differential expression of miR200a-3p and miR21 in grade II-III and grade IV gliomas: evidence that miR200a-3p is regulated by O(6)-methylguanine methyltransferase and promotes temozolomide responsiveness. Cancer Biol Ther 15(7):938–950

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  51. Barbano R, Palumbo O, Pasculli B, Galasso M, Volinia S, D’Angelo V et al (2014) A miRNA signature for defining aggressive phenotype and prognosis in gliomas. PLoS ONE 9(10):e108950

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  52. Lages E, Guttin A, El Atifi M, Ramus C, Ipas H, Dupre I et al (2011) MicroRNA and target protein patterns reveal physiopathological features of glioma subtypes. PLoS ONE 6(5):e20600

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  53. Conti A, Aguennouz M, La Torre D, Tomasello C, Cardali S, Angileri FF et al (2009) miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors. J Neurooncol 93(3):325–332

    Article  CAS  PubMed  Google Scholar 

  54. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116(6):597–602

    Article  CAS  PubMed  Google Scholar 

  55. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765–773

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  56. Lang MF, Yang S, Zhao C, Sun G, Murai K, Wu X et al (2012) Genome-wide profiling identified a set of miRNAs that are differentially expressed in glioblastoma stem cells and normal neural stem cells. PLoS ONE 7(4):e36248

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  57. Gal H, Pandi G, Kanner AA, Ram Z, Lithwick-Yanai G, Amariglio N et al (2008) MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells. Biochem Biophys Res Commun. 376(1):86–90

    Article  CAS  PubMed  Google Scholar 

  58. Lavon I, Zrihan D, Granit A, Einstein O, Fainstein N, Cohen MA et al (2010) Gliomas display a microRNA expression profile reminiscent of neural precursor cells. Neuro Oncol. 12(5):422–433

    PubMed Central  CAS  PubMed  Google Scholar 

  59. Srinivasan S, Patric IR, Somasundaram K (2011) A ten-microRNA expression signature predicts survival in glioblastoma. PLoS ONE 6(3):e17438

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  60. Zhang W, Zhang J, Yan W, You G, Bao Z, Li S et al (2013) Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. Cancer 119(4):814–824

    Article  CAS  PubMed  Google Scholar 

  61. Yan W, Li R, Liu Y, Yang P, Wang Z, Zhang C et al (2014) MicroRNA expression patterns in the malignant progression of gliomas and a 5-microRNA signature for prognosis. Oncotarget. 5(24):12908–12915

    Article  PubMed Central  PubMed  Google Scholar 

  62. Lakomy R, Sana J, Hankeova S, Fadrus P, Kren L, Lzicarova E et al (2011) MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients. Cancer Sci 102(12):2186–2190

    Article  CAS  PubMed  Google Scholar 

  63. Ma R, Yan W, Zhang G, Lv H, Liu Z, Fang F et al (2012) Upregulation of miR-196b confers a poor prognosis in glioblastoma patients via inducing a proliferative phenotype. PLoS ONE 7(6):e38096

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  64. Qiu S, Lin S, Hu D, Feng Y, Tan Y, Peng Y (2013) Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients. J Transl Med. 11:10

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  65. Lu S, Wang S, Geng S, Ma S, Liang Z, Jiao B (2012) Increased expression of microRNA-17 predicts poor prognosis in human glioma. J Biomed Biotechnol. 2012:970761

    PubMed Central  PubMed  Google Scholar 

  66. Lai NS, Dong QS, Ding H, Miao ZL, Lin YC (2014) MicroRNA-210 overexpression predicts poorer prognosis in glioma patients. J Clin Neurosci. 21(5):755–760

    Article  CAS  PubMed  Google Scholar 

  67. Lu S, Wang S, Geng S, Ma S, Liang Z, Jiao B (2013) Upregulation of microRNA-224 confers a poor prognosis in glioma patients. Clin Transl Oncol 15(7):569–574

    Article  CAS  PubMed  Google Scholar 

  68. Sun J, Shi H, Lai N, Liao K, Zhang S, Lu X (2014) Overexpression of microRNA-155 predicts poor prognosis in glioma patients. Med Oncol 31(4):911

    Article  PubMed  CAS  Google Scholar 

  69. Men D, Liang Y, Chen L (2014) Decreased expression of microRNA-200b is an independent unfavorable prognostic factor for glioma patients. Cancer Epidemiol. 38(2):152–156

    Article  PubMed  Google Scholar 

  70. Hou SX, Ding BJ, Li HZ, Wang L, Xia F, Du F et al (2013) Identification of microRNA-205 as a potential prognostic indicator for human glioma. J Clin Neurosci. 20(7):933–937

    Article  CAS  PubMed  Google Scholar 

  71. Wang S, Lu S, Geng S, Ma S, Liang Z, Jiao B (2013) Expression and clinical significance of microRNA-326 in human glioma miR-326 expression in glioma. Med Oncol 30(1):373

    Article  PubMed  CAS  Google Scholar 

  72. Huang D, Qiu S, Ge R, He L, Li M, Li Y et al (2015) miR-340 suppresses glioblastoma multiforme. Oncotarget 6:9257–9270

    Article  PubMed Central  PubMed  Google Scholar 

  73. Guan Y, Chen L, Bao Y, Pang C, Cui R, Li G et al (2015) Downregulation of microRNA-504 is associated with poor prognosis in high-grade glioma. Int J Clin Exp Pathol. 8(1):727–734

    PubMed Central  PubMed  Google Scholar 

  74. Chang C, Shi H, Wang C, Wang J, Geng N, Jiang X et al (2012) Correlation of microRNA-375 downregulation with unfavorable clinical outcome of patients with glioma. Neurosci Lett 531(2):204–208

    Article  CAS  PubMed  Google Scholar 

  75. Bracken CP, Li X, Wright JA, Lawrence DM, Pillman KA, Salmanidis M et al (2014) Genome-wide identification of miR-200 targets reveals a regulatory network controlling cell invasion. EMBO J 33(18):2040–2056

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  76. Stylli SS, Kaye AH, Lock P (2008) Invadopodia: at the cutting edge of tumour invasion. J Clin Neurosci. 15(7):725–737

    Article  CAS  PubMed  Google Scholar 

  77. Stylli SS, Stacey TT, Kaye AH, Lock P (2012) Prognostic significance of Tks5 expression in gliomas. J Clin Neurosci. 19(3):436–442

    Article  CAS  PubMed  Google Scholar 

  78. Parker NR, Khong P, Parkinson JF, Howell VM, Wheeler HR (2015) Molecular heterogeneity in glioblastoma: potential clinical implications. Front Oncol. 5:55

    PubMed Central  PubMed  Google Scholar 

  79. Kim TM, Huang W, Park R, Park PJ, Johnson MD (2011) A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs. Cancer Res 71(9):3387–3399

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  80. Li R, Gao K, Luo H, Wang X, Shi Y, Dong Q et al (2014) Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastoma. J Exp Clin Cancer Res. 33:9

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  81. Hayes J, Thygesen H, Tumilson C, Droop A, Boissinot M, Hughes TA et al (2015) Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature. Mol Oncol. 9(3):704–714

    Article  CAS  PubMed  Google Scholar 

  82. Haemmig S, Baumgartner U, Gluck A, Zbinden S, Tschan MP, Kappeler A et al (2014) miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas. Cell Death Dis 5:e1279

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Slaby O, Lakomy R, Fadrus P, Hrstka R, Kren L, Lzicarova E et al (2010) MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients. Neoplasma. 57(3):264–269

    Article  CAS  PubMed  Google Scholar 

  84. Baraniskin A, Kuhnhenn J, Schlegel U, Maghnouj A, Zollner H, Schmiegel W et al (2012) Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neuro Oncol. 14(1):29–33

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  85. Teplyuk NM, Mollenhauer B, Gabriely G, Giese A, Kim E, Smolsky M et al (2012) MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro Oncol. 14(6):689–700

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  86. Akers JC, Ramakrishnan V, Kim R, Phillips S, Kaimal V, Mao Y et al (2015) miRNA contents of cerebrospinal fluid extracellular vesicles in glioblastoma patients. J Neurooncol 123(2):205–216

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  87. Akers JC, Ramakrishnan V, Kim R, Skog J, Nakano I, Pingle S et al (2013) MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development. PLoS ONE 8(10):e78115

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  88. Liu Y, Zhang J, Han R, Liu H, Sun D, Liu X (2015) Downregulation of serum brain specific microRNA is associated with inflammation and infarct volume in acute ischemic stroke. J Clin Neurosci. 22(2):291–295

    Article  CAS  PubMed  Google Scholar 

  89. Sun XY, Lu J, Zhang L, Song HT, Zhao L, Fan HM et al (2015) Aberrant microRNA expression in peripheral plasma and mononuclear cells as specific blood-based biomarkers in schizophrenia patients. J Clin Neurosci. 22(3):570–574

    Article  CAS  PubMed  Google Scholar 

  90. Dong L, Li Y, Han C, Wang X, She L, Zhang H (2014) miRNA microarray reveals specific expression in the peripheral blood of glioblastoma patients. Int J Oncol 45(2):746–756

    CAS  PubMed  Google Scholar 

  91. Roth P, Wischhusen J, Happold C, Chandran PA, Hofer S, Eisele G et al (2011) A specific miRNA signature in the peripheral blood of glioblastoma patients. J Neurochem 118(3):449–457

    Article  CAS  PubMed  Google Scholar 

  92. Wang Q, Li P, Li A, Jiang W, Wang H, Wang J et al (2012) Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma. J Exp Clin Cancer Res. 31:97

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  93. Yang C, Wang C, Chen X, Chen S, Zhang Y, Zhi F et al (2013) Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer 132(1):116–127

    Article  CAS  PubMed  Google Scholar 

  94. Zhi F, Shao N, Wang R, Deng D, Xue L, Wang Q et al (2014) Identification of 9 serum microRNAs as potential noninvasive biomarkers of human astrocytoma. Neuro Oncol. doi:10.1371/journal.pone.0105734

    PubMed  Google Scholar 

  95. Shao N, Wang L, Xue L, Wang R, Lan Q (2015) Plasma miR-454-3p as a potential prognostic indicator in human glioma. Neurol Sci. 36(2):309–313

    Article  PubMed  Google Scholar 

  96. Ilhan-Mutlu A, Wagner L, Wohrer A, Furtner J, Widhalm G, Marosi C et al (2012) Plasma MicroRNA-21 concentration may be a useful biomarker in glioblastoma patients. Cancer Invest 30(8):615–621

    Article  CAS  PubMed  Google Scholar 

  97. Lai NS, Wu DG, Fang XG, Lin YC, Chen SS, Li ZB et al (2015) Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma. Br J Cancer 112(Suppl):1241–1246

    Article  CAS  PubMed  Google Scholar 

  98. Zhang R, Pang B, Xin T, Guo H, Xing Y, Xu S et al (2015) Plasma miR-221/222 family as novel descriptive and prognostic biomarkers for glioma. Mol Neurobiol 48(1):37

    Google Scholar 

  99. Wu J, Li L, Jiang C (2014) Identification and evaluation of serum MicroRNA-29 family for glioma screening. Mol Neurobiol. 1:1–7

    Google Scholar 

  100. Wei X, Chen D, Lv T, Li G, Qu S (2014) Serum MicroRNA-125b as a Potential Biomarker for Glioma Diagnosis. Mol Neurobiol. 50:896–913

    Article  CAS  Google Scholar 

  101. Manterola L, Guruceaga E, Gallego Perez-Larraya J, Gonzalez-Huarriz M, Jauregui P, Tejada S et al (2014) A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. Neuro Oncol. 16(4):520–527

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  102. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M et al (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10(12):1470–1476

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  103. Siegal T (2015) Clinical impact of molecular biomarkers in gliomas. J Clin Neurosci. 22(3):437–444

    Article  CAS  PubMed  Google Scholar 

  104. Ciafre SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G et al (2005) Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun. 334(4):1351–1358

    Article  CAS  PubMed  Google Scholar 

  105. Chan JA, Krichevsky AM, Kosik KS (2005) MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65(14):6029–6033

    Article  CAS  PubMed  Google Scholar 

  106. Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M et al (2008) miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 6:14

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  107. Sasayama T, Nishihara M, Kondoh T, Hosoda K, Kohmura E (2009) MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. Int J Cancer 125(6):1407–1413

    Article  CAS  PubMed  Google Scholar 

  108. Hua D, Mo F, Ding D, Li L, Han X, Zhao N et al (2012) A catalogue of glioblastoma and brain MicroRNAs identified by deep sequencing. OMICS 16(12):690–699

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  109. Skalsky RL, Cullen BR (2011) Reduced expression of brain-enriched microRNAs in glioblastomas permits targeted regulation of a cell death gene. PLoS ONE 6(9):e24248

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  110. Sana J, Radova L, Lakomy R, Kren L, Fadrus P, Smrcka M et al (2014) Risk score based on microRNA expression signature is independent prognostic classifier of glioblastoma patients. Carcinogenesis 35(12):2756–2762

    Article  PubMed  Google Scholar 

  111. Zadran S, Remacle F, Levine R (2014) Surprisal analysis of glioblastoma multiform (GBM) microRNA dynamics unveils tumor specific phenotype. PLoS ONE 9(9):e108171

    Article  PubMed Central  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Sciences Building, Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, Victoria, 3050, Australia

    Zammam Areeb, Stanley S. Stylli, Andrew P. Morokoff, Andrew H. Kaye & Rodney B. Luwor

  2. Department of Neurosurgery, The Royal Melbourne Hospital, Parkville, Victoria, 3050, Australia

    Stanley S. Stylli, Andrew P. Morokoff & Andrew H. Kaye

  3. ACRF Translational Research Laboratory, Royal Melbourne Hospital, Parkville, Victoria, 3050, Australia

    Rachel Koldej & David S. Ritchie

  4. Haematology and Immunology Translational Research Laboratory, Cancer Immunology Research Department, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

    Rachel Koldej & David S. Ritchie

  5. Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia

    Rachel Koldej & David S. Ritchie

  6. Center for Neuro-Oncology, Davidoff Institute of Oncology, Rabin Medical Center, Petach Tokva, Israel

    Tali Siegal

Authors
  1. Zammam Areeb
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stanley S. Stylli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rachel Koldej
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David S. Ritchie
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tali Siegal
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Andrew P. Morokoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Andrew H. Kaye
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rodney B. Luwor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rodney B. Luwor.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Areeb, Z., Stylli, S.S., Koldej, R. et al. MicroRNA as potential biomarkers in Glioblastoma. J Neurooncol 125, 237–248 (2015). https://doi.org/10.1007/s11060-015-1912-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-015-1912-0

Keywords

Search

Navigation